Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors

Journal of Medical Economics

Volumn 13, Issue 4, 2010, Pages 681-690

  Blanke, Charles D ^a   Huse, Daniel M ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b THOMSON REUTERS   (United States)

Author keywords

Cost effectiveness; Cost utility; Gastrointestinal stromal tumor; Imatinib; Markov model; Mesylate; Sunitinib

Indexed keywords

IMATINIB; PLACEBO; SUNITINIB;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE SYSTEM; HIDDEN MARKOV MODEL; HUMAN; LITERATURE; MEDLINE; OPEN STUDY; OUTCOME ASSESSMENT; REVIEW;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MODELS, ECONOMIC; NEOPLASM METASTASIS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES;

EID: 78650065559     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.534670     Document Type: Review

References (48)

1. Goettsch WG, Bos SD, Breekveldt-Postma N, et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 2005;41:2868-72
2. Mucciarini C, Rossi G, Bertolini F, et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 2007;7:230
3. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005;103:821-9
4. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000;15:1293-301
5. Rubio J, Marcos-Gragera R, Ortiz MR, et al. Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain. Eur J Cancer 2007;43:144-8
6. Tran T, Davila JA, El Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005;100:162-8
7. Tryggvason G, Gislason HG, Magnusson MK, et al. Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a populationbased incidence and pathologic risk stratification study. Int J Cancer 2005;117:289-93
8. NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma. V2.2010. Available at: http://www.nccn.org. Last access April 14, 2010
9. Dematteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8
10. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2010;8(Suppl 2):S1-S41
11. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10
12. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80
13. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of plateletderived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-7
14. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6
15. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-5
16. Blackstein ME, Blay JY, Corless C, et al. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol 2006; 20:157-63
17. Casali PG, Blay JY. On behalf of the ESMO Guidelines Working Group. Gastrointestinal stromal tumours: ESMO Clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5): v98-102
18. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-103
19. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34
20. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41:1751-7
21. Judson IR. Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype. J Clin Oncol 2008;26:5322-5
22. Van Glabbeke M. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a metaanalysis based on 1640 patients. The GIST Meta-Analysis group (MetaGIST). J Clin Oncol 2010;28:1247-53
23. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-80
24. Hopkins TG, Marples M, Stark D. Sunitinib in the management of gastrointestinal stromal tumours (GISTs). Eur J Surg Oncol 2008;34:844-50
25. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26:5352-9
26. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008;53:245-66
27. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368: 1329-38
28. Demetri GD, Huang X, Garrett CR, et al. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure. J Clin Oncol (Meeting Abstracts) 2008;26:10524
29. Demetri GD, Casali PG, Blay JY, et al. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2009;15:5910-16
30. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41
31. Wiebe L, Kasza KE, Maki RG, et al. Activity of sorafenib (SOR) in patients ( pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol (Meeting Abstracts) 2008;26:10502
32. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44
33. Adenis A, Cassier PA, Bui BN, et al. Does interruption of imatinib (IM) in responding patients after three years of treatment influence outcome of patients with advanced GIST included in the BFR14 trial? J Clin Oncol 2008;26(Suppl): abstract 10522
34. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007;25:1107-13
35. Rios M, LeCesne A, Bui B, et al. Interruption of imatinib (IM) in GIST patients with advanced disease after one year of treatment: Updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival. J Clin Oncol (Meeting Abstracts) 2007;25:10016
36. Huse DM, von Mehren M, Lenhart G, et al. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. Clin Drug Investig 2007;27:85-93
37. Mabasa VH, Taylor SC, Chu CC, et al. Verification of imatinib costeffectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study). J Oncol Pharm Pract 2008;14:105-12
38. Wilson J, Connock M, Song F, et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess 2005;9:1-142
39. Chabot I, LeLorier J, Blackstein ME. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour. Eur J Cancer 2008;44:972-7
40. Paz-Ares L, Garcia dMX, Grande E, et al. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib. Clin Transl Oncol 2008;10:831-9
41. Contreras-Hernandez I, Mould-Quevedo JF, Silva A, et al. A pharmacoeconomic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours. Br J Cancer 2008;98:1762-8
42. Benjamin RS, Rankin C, Fletcher CD. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Interrgroup S0033 early results. Proc Am Soc Clin Oncol 2003;22:(abstract 3271)
43. Verweij J, Casali PG, Zalcberg J. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized Phase III trial from the EORTCSTBSG, ISG and AGITG. Proc Am Soc Clin Oncol 2003;22:(abstract 3272)
44. Motzer RJ, Hoosen S, Bello CL, et al. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 2006;15:553-61
45. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000;18:3302-17
46. El Ouagari K, Huse DM. Cost-effectiveness of imatinib in the treatment of advanced gastrointestinal stromal tumors (GIST): Canadian perspective. 33rd ESMO Congress, Stockholm, Sweden, September 12-16, 2008. Abstract 722P
47. Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006;24:1-19
48. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24